KalVista Pharmaceuticals, Inc..
KALV.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products
KalVista Pharmaceuticals, Inc. is a pharmaceutical company focused on the discovery, development, and commercialization of small molecule protease inhibitors for diseases with significant unmet needs. Their primary focus is on developing therapies for hereditary angioedema (HAE), a rare genetic diso...Show More
Better Health for All
50
KalVista Pharmaceuticals demonstrates a strong commitment to 'Better Health for All' through its focus on developing treatments for Hereditary Angioedema (HAE), a rare and potentially life-threatening genetic condition. The FDA approval of EKTERLY® (sebetralstat) as an oral on-demand treatment for acute HAE attacks in adults and pediatric patients aged 12 years and older marks a significant advancement, offering a new treatment option after over a decade
1
. Clinical trials (KONFIDENT) showed significantly faster symptom relief compared to placebo, with a safety profile consistent with placebo
2
. The KONFIDENT-S open-label extension trial showed a median symptom relief time of 10 minutes post-attack onset
3
. KalVista is also conducting pediatric trials (KONFIDENT-KID) to expand access to children under 12
4
. The KalVista Cares™ program aims to streamline access and reduce administrative burdens for patients
5
. The company has invested in research and development, with $12.6 million spent in Q3 2025
6
. These efforts align with improving health outcomes and accessibility for HAE patients. **Assessment Limitations**: Specific pricing details and the extent of vulnerable population reach are not fully detailed in the provided evidence.
Fair Money & Economic Opportunity
0
No evidence available to assess KalVista Pharmaceuticals, Inc. on Fair Money & Economic Opportunity.
Fair Pay & Worker Respect
0
No specific, quantitative data points for KalVista Pharmaceuticals, Inc. regarding living wage coverage, CEO-median pay ratio, collective bargaining share, safety incident rate, pay equity ratio, worker engagement score, turnover rate, labor violation incidents, insecure contract share, or health insurance coverage were found in the provided articles.
1
The available information for other companies in the pharmaceutical industry does not apply to KalVista Pharmaceuticals, Inc.
Fair Trade & Ethical Sourcing
0
No evidence available to assess KalVista Pharmaceuticals, Inc. on Fair Trade & Ethical Sourcing.
Honest & Fair Business
-40
The company has a formal whistleblower protection policy that includes a hotline, anonymity protection, and a prohibition on retaliation.
1
It also has an anti-corruption policy that incorporates the PhRMA Code and OIG Guidance, addressing potential fraud and abuse risks such as kickbacks and drug sample regulations, but the article does not specify training frequency or effectiveness metrics.
2
The board of directors includes Bethany L. Sensenig, who joined the Audit Committee.
3
The company has an ESG Risk Rating of 37.4 from Sustainalytics, placing it in the bottom quartile (705 out of 848) within the Pharmaceuticals industry.
4
Kind to Animals
-70
KalVista Pharmaceuticals conducts preclinical laboratory and animal tests, including toxicity studies and dosing to primates, with no evidence of employing non-animal testing methods.
1
The company explicitly states that no specific animal testing policy is mentioned in the provided documents.
2
While KalVista engages with regulatory bodies like the FDA and EMA, there is no mention of engagement on animal welfare policies.
3
No War, No Weapons
0
No evidence available to assess KalVista Pharmaceuticals, Inc. on No War, No Weapons.
Planet-Friendly Business
0
No specific, quantifiable evidence was found in the provided articles for any of the KPIs related to Planet-Friendly Business. The articles primarily contain financial information, general ESG risk ratings, and aggregated ESG impact scores, but lack concrete data points such as total emissions, renewable energy percentages, waste diversion rates, or details on environmental policies and initiatives. For instance, while 'GHG Emissions' and 'Waste' are mentioned as negative impact categories in one article, these are high-level scores and not the specific quantitative metrics required by the rubric.
1
Respect for Cultures & Communities
0
No specific, concrete evidence was found in the provided articles to assess KalVista Pharmaceuticals, Inc. against any of the Key Performance Indicators for the 'Respect for Cultures & Communities' ethical value. The articles discuss patient support and FDA approval, but do not contain data related to formal partnerships with indigenous or local community groups, revenue reinvested in local community development, cultural appropriation incidents, cultural impact assessment protocols, local employment ratios, grievance mechanisms for community concerns, FPIC processes, community governance inclusion, cultural preservation investment, local procurement, indigenous supplier engagement, cultural site protection, social license to operate, charitable giving to cultural heritage organizations, community fund allocation, language inclusivity, cultural incident response, or cultural sensitivity training.
1
Safe & Smart Tech
0
KalVista Pharmaceuticals has a cybersecurity risk management program aligned with the NIST Cybersecurity Framework and ISO/IEC 27001, performing a formal risk assessment annually.
1
The company implements protections including firewalls, endpoint detection and response, anti-malware, immutable backups, multi-factor authentication schemes, data encryption, and security system information event monitoring.
2
It conducts periodic intrusion and penetration testing through third parties and utilizes threat intelligence services.
3
The company maintains a security awareness program with mandatory semi-annual training and automated e-mail based phishing tests, using results for continuous improvement.
4
The Audit Committee oversees cybersecurity risks.
5
Directors are expected to maintain confidentiality of non-public information.
6
KalVista is subject to and aims to comply with various privacy and healthcare regulations, including HIPAA, HITECH, and SEC cybersecurity disclosure rules, and has a Code of Business Conduct and Ethics adopted in March 2025 that emphasizes regulatory compliance and confidentiality.
7
The company's website is intended for users 18 years or older in the US and UK, and its relationship with users is governed by Terms & Conditions and a Privacy Notice.
8
Users can opt-in/out of SMS/MMS text messaging programs.
9
The company is not aware of any material risks from cybersecurity threats that have materially affected or are reasonably likely to materially affect the Company as of July 11, 2024.
10
Zero Waste & Sustainable Products
0
The provided articles do not contain specific, quantitative data points for KalVista Pharmaceuticals, Inc. that can be mapped to any of the KPIs in the Zero Waste & Sustainable Products rubric. While Article 0 mentions a 'Negative Waste Score' of -0.49.
1
this is an aggregated, high-level score from an ESG model and not a concrete metric (such as a percentage, number of initiatives, or reduction amount) that aligns with the specific quantitative thresholds defined for any of the KPIs. Therefore, no KPIs can be scored based on the available evidence.